ChondrosarcomaSymptoms, Doctors, Treatments, Advances & More
Chondrosarcoma Overview
Learn About Chondrosarcoma
View Main Condition: Brain Tumor
Silvia Stacchiotti practices practicing medicine in Milan, Italy. Ms. Stacchiotti is rated as an Elite expert by MediFind in the treatment of Chondrosarcoma. She is also highly rated in 28 other conditions, according to our data. Her clinical expertise encompasses Solitary Fibrous Tumor, Adult Soft Tissue Sarcoma, Hemangioendothelioma, Epithelioid Sarcoma, and Synovectomy.
Emanuela Palmerini is an Oncologist practicing medicine in Miami, Florida. Dr. Palmerini is rated as an Elite provider by MediFind in the treatment of Chondrosarcoma. She is also highly rated in 14 other conditions, according to our data. Her clinical expertise encompasses Adult Soft Tissue Sarcoma, Osteosarcoma, Chondrosarcoma, and Ewing Sarcoma. Dr. Palmerini is currently accepting new patients.
UPMC Hillman Cancer Center
Melissa Burgess is a Hematologist Oncology provider practicing medicine in Pittsburgh, Pennsylvania. She has been practicing medicine for over 17 years. Dr. Burgess is rated as an Elite provider by MediFind in the treatment of Chondrosarcoma. She is also highly rated in 41 other conditions, according to our data. Her clinical expertise encompasses Adult Soft Tissue Sarcoma, Liposarcoma, Merkel Cell Carcinoma, Chondrosarcoma, and Gamma Knife Radiosurgery. Dr. Burgess is board certified in American Board Of Internal Medicine. Dr. Burgess is currently accepting new patients.
Summary: The study participant has been diagnosed with non-rhabdomyosarcoma (NRSTS). Primary Objectives Intermediate-Risk * To estimate the 3-year event-free survival for intermediate-risk patients treated with ifosfamide, doxorubicin, pazopanib, surgery, and maintenance pazopanib, with or without RT. * To characterize the pharmacokinetics of pazopanib and doxorubicin in combination with ifosfamide in inte...
Summary: This is a single-arm, phase II study that will enroll a total of 45 subjects. All subjects will have a confirmed diagnosis of metastatic or unresectable soft tissue sarcoma or bone sarcoma. All subjects must have intact Rb, identified at the time of screening, by immunohistochemistry testing of submitted tumor specimen. Subjects will receive Abemaciclib 200 mg twice daily until progression or disc...


